Home › Free Stock Grades › REPL
Replimune Group, Inc. (REPL) Stock Grade
REPL · Healthcare
C-
Market Cap
$1.1B
P/E Ratio
—
Revenue Growth (YoY)
0.0%
Net Margin
0.0%
Return on Equity
—
Dividend Yield
None
About Replimune Group, Inc.'s fundamentals
Replimune is a biotechnology company with a market capitalization of $1.1 billion that reported flat revenue growth year-over-year at 0.0% and posted a net loss in its latest annual statement, resulting in a net margin of 0.0%. The company does not currently pay dividends and lacks positive earnings metrics, which is typical for early-stage biotech firms still in development phases. With no meaningful profitability, traditional valuation metrics like P/E ratio and return on equity are not applicable.